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Abstract
Background: Epidermal growth factor receptor (EGFR) inhibitors have shown only modest clinical activity when used as
single agents to treat cancers. They decrease tumor cell expression of hypoxia-inducible factor 1-a (HIF-1a) and vascular
endothelial growth factor (VEGF). Hypothesizing that this might normalize tumor vasculature, we examined the effects of
the EGFR inhibitor erlotinib on tumor vascular function, tumor microenvironment (TME) and chemotherapy and
radiotherapy sensitivity.
Methodology/Principal Findings: Erlotinib treatment of human tumor cells in vitro and mice bearing xenografts in vivo led
to decreased HIF-1a and VEGF expression. Treatment altered xenograft vessel morphology assessed by confocal microscopy
(following tomato lectin injection) and decreased vessel permeability (measured by Evan’s blue extravasation), suggesting
vascular normalization. Erlotinib increased tumor blood flow measured by Power Doppler ultrasound and decreased
hypoxia measured by EF5 immunohistochemistry and tumor O2 saturation measured by optical spectroscopy. Predicting
that these changes would improve drug delivery and increase response to chemotherapy and radiation, we performed
tumor regrowth studies in nude mice with xenografts treated with erlotinib and either radiotherapy or the
chemotherapeutic agent cisplatin. Erlotinib therapy followed by cisplatin led to synergistic inhibition of tumor growth
compared with either treatment by itself (p,0.001). Treatment with erlotinib before cisplatin led to greater tumor growth
inhibition than did treatment with cisplatin before erlotinib (p=0.006). Erlotinib followed by radiation inhibited tumor
regrowth to a greater degree than did radiation alone, although the interaction between erlotinib and radiation was not
synergistic.
Conclusions/Significance: EGFR inhibitors have shown clinical benefit when used in combination with conventional
cytotoxic therapy. Our studies show that targeting tumor cells with EGFR inhibitors may modulate the TME via vascular
normalization to increase response to chemotherapy and radiotherapy. These studies suggest ways to assess the response
of tumors to EGFR inhibition using non-invasive imaging of the TME.
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Introduction
The idea of manipulating the tumor microenvironment (TME)
to improve cancer therapy has been around for decades; however,
finding ways in which to do this in the clinic has proven difficult.
The response of tumors to radiation depends on factors in the
TME including tumor cell-extracellular matrix interactions [1]
and tumor oxygenation [2]. Efforts to decrease tumor hypoxia
using hyperbaric oxygen have had limited success in increasing
radiosensitivity [3]. In the 1970’s, Folkman proposed the concept
of targeting blood vessels within tumors to control their growth [4].
There are currently a number of anti-angiogenic drugs in clinical
use but, used as single agents, these have had modest success in
patient trials [5,6]. More recently Jain and colleagues showed that
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aberrant tumor vasculature in such as way as to improve
oxygenation and blood flow that could enhance the efficacy of
subsequent radiation and chemotherapy [7,8]. Their approach
relied on using agents that directly target vascular endothelial
growth factor (VEGF) or its receptor (VEGFR) on endothelial
cells. In the current study we use a different approach to alter the
TME, to target the tumor cells to reduce VEGF secretion, thereby
indirectly leading to vascular normalization.
The advent of molecularly targeted agents opens the possibility
for inhibiting specific molecules and pathways critical for tumor
growth, invasion and metastasis, and most of these agents target
the tumor cells themselves. Tumor cells may be targeted by
inhibiting the epidermal growth factor (EGFR). EGFR is
overexpressed and activated in a variety of tumors and provides
an attractive target for anti-cancer therapy (reviewed in [9]). In the
early 1980’s Mendelsohn and colleagues developed the monoclo-
nal antibody C225 (now called cetuximab) and showed it to have
efficacy in inhibiting cancer cell growth both in vitro and in vivo
[10]. Since then, a variety of EGFR inhibitors, both monoclonal
antibodies and small molecular kinase inhibitors such as gefitinib
and erlotinib have been developed and tested in clinical trials.
There is a clear connection between EGFR signaling and VEGF
expression. EGF induces VEGF in many cell lines through
increased VEGF mRNA transcription [11–13]. EGFR stimulation
activates many downstream signaling pathways including the
PI3K/Akt pathway [9]. Activated Akt increases expression of a
key transcription factor, hypoxia-inducible factor-1a (HIF-1a)
[14,15]. One of the many transcriptional targets of HIF-1a is the
VEGF gene. Conversely, pharmacological inhibition of EGFR can
decrease VEGF expression and consequently angiogenesis in
many tumor types [16–20].
Because EGFR inhibition can downregulate HIF-1a expression
in tumor cells and decrease VEGF secretion, we hypothesized that
erlotinib treatment would indirectly lead to vascular normalization
and decrease tumor hypoxia. We explored the effects of erlotinib on
the TME, specifically on vessel morphology, vascular permeability,
tumor blood flow and tumor oxygenation. We found profound
alterations in all of these parameters, which led us to investigate the
effects of this agent on the subsequent response of tumors to
chemotherapy and radiotherapy. Our results offer insight into how
targeting tumor cells with EGFR inhibitors may modulate the TME
to improve sensitivity to chemotherapy or radiotherapy. They have
clinical implications about the sequencing and timing of these
agents with conventional therapy and suggest ways to monitor their
effects on the TME in the clinic using non-invasive imaging.
Methods
Ethics statement
All animal work was conducted according to relevant national
and international guidelines. For details please refer to subsection
entitled Mouse studies.
Tissue Culture and Reagents
SQ20B head and neck squamous cell carcinoma, H226 and
H292 non-small cell lung cancer cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM, 4500 mg/liter glucose, Life
Technologies, Inc.) containing 10% fetal bovine serum (Atlanta
Biologicals) and grown in an incubator containing 5% carbon
dioxide and 21% oxygen.
Erlotinib (Tarceva; OSI Pharmaceuticals; Melville, NY) was
prepared as a 10 mM stock solution by taking an erlotinib tablet,
crushing it and dissolving in DMSO. Cetuximab (Erbitux;
ImClone, Branchburg, NJ) was prepared as directed by the
manufacturer (2 mg/ml stock solution). siRNA was purchased
from Dharmacon: EGFR siRNA SMARTpool (M-003114-03)
and non-targeting #1-5 (control) siRNA (D-001210-02-20).
Optimem media and Oligofectamine, purchased from Life-
Technologies, (Rockville, MD), were used as per the manufactur-
er’s instructions.
Protein Extraction, Western Blot Analysis
For protein isolation, cells were washed once with cold PBS
containing 1 mM EDTA, then solubilized by adding lysis buffer
(1% Triton X-100, 20 mM Tris, pH 7.6, 150 mM NaCl, 2 mM
EDTA, 10% glycerol, 1 mM DTT, 1 mM orthovanadate, 2 mM
PMSF) directly on the cells. Lysates were transferred into 1.5 ml
Eppendorf tubes and centrifuged at 12,000 rpm for 10 minutes at
4uC. Supernatants were transferred to a fresh tube and frozen on
dry ice. Protein concentrations were determined using a BCA
Protein Assay kit (Pierce, Rockford, IL). For Western blotting, an
equal amount of total protein was separated by SDS/PAGE on a
6% polyacrylamide gel.
For Western blotting, equal amounts of total protein were run in
each lane of an SDS-PAGE gel (12% acrylamide). Each protein
sample was mixed with an equal volume of 26Laemmli buffer and
boiled at 95uC for 5 minutes before loading onto the gel. After
completion of gel electrophoresis, protein was transferred to a
Hybond nitrocellulose membrane over one hour using a blotting
apparatus. The following antibodies were used: monoclonal anti-
phospho Akt antibody that recognizes P-S473 (New England Biolabs,
Ipswich, MA), anti-Akt antibody, anti-HIFa antibody (clone H1a67,
Novus Biologicals, Littleton, CO) at a dilution of 1:1000, anti-b-actin
antibody (Sigma, St. Louis, MO) at a 1:1,000 dilution. The secondary
antibody used for these blots was a goat anti-mouse antibody (Biorad,
Hercules, CA). Antibody binding was detected by chemilumines-
cence using an ECL kit (Amersham Pharmacia, Piscataway, NJ).
Mouse studies
Pathogen free female Ncr-nu/nu mice were obtained from
Charles River Laboratory Inc. (Wilmington, MA) and housed in
the vivarium of the University of Pennsylvania Laboratory Animal
Resources. All the experiments were carried out in accordance
with the protocols approved by University Institutional Animal
Care and Use Committee guidelines. No more than 4 adult mice
were housed in a cage to avoid overcrowding. The weight of the
mice was monitored. As per IACUC regulations, a veterinarian
would have to be contacted when any of the following occurred:
weight dropped below 10% of the baseline, the mice appeared less
active, depressed, sunken eyes, abnormal posture, mice had
reduced feed or water intake (even lower than the restricted
amounts), or showed signs of pain or distress. Mice were allowed to
move freely most of the time. They were restrained only for brief
periods, usually minutes, for specific research procedures.
Appropriate anesthesia was administered to mice undergoing
procedures that caused more than momentary or slight pain or
distress. For tumor regrowth studies, the size of the subcutaneous
tumors was monitored 3 times a week. Mice were sacrificed when
tumors exceeded 10% of body weight.
To implant xenografts, mice at the age of five - seven weeks
were subcutaneously injected with 1–2610
6 cells subcutaneously
into the flank. Palpable tumors were generally observed 7–10 days
after injection.
Prior to the start of experiments, mice were housed individually
and daily food consumption was measured for 5 days. During the
course of erlotinib treatment mice were also housed separately so
that they could be fed a fixed amount of transgenic dough diet
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diet so that based on the average daily intake of each mouse; the
targeted daily erlotinib dose was 50 mg/kg/day. During the
treatment phase of the study, all the feed was eaten daily by each
animal. No additional food was given. Body weight was measured
at the start and end of feeding to ensure mice did not lose weight.
Cisplatin (Bedford Laboratories, Bedford, OH) was adminis-
tered intraperitoneally. 1 ml of cisplatin stock (1 mg/ml) was
diluted up in 10 ml of 0.9% saline. 250 ml was injected per mouse
(average of 21 gm. per mouse). Bevacizumab (Avastin; Genentech,
South San Francisco, CA) at 25 mg/ml and cisplatin were
administered intraperitoneally.
VEGF ELISA
Tumors were excised and weighed, then homogenized in 1 ml of
1x PBS (0.1% heparin). VEGFprotein concentration was determined
from tissue homogenate (100 ml) using a commercial kit (R & D
Systems) according to the manufacturer’s protocol. VEGF protein
levels were normalized to their weights and plotted on y-axis.
Vascular permeability assay
Evans blue (30 mg/kg) was injected intravenously and allowed
to circulate for 6 hrs. Thereafter mice were sacrificed and tumors
were excised, dried (60uC, 16 hr), and weighed before Evans blue
extraction in 1 ml of formamide at 55uC for 16 hr. Evans blue
content was quantified by spectrophotometer reading at 620 nm.
Power Doppler studies
Contrast-enhanced power Doppler imaging was performed as
described previously [21]. In brief, mice bearing SQ20B
xenografts were anesthetized and injected with 0.02 ml of
microbubble contrast agent (Definity, Lantheus Medical Imaging,
Billerica, MA, USA) and power Doppler imaging was performed
using a broadband 7–15 MHz probe (HDI500 SonoCT, Philips,
Bothell, WA, USA). Power Doppler images were acquired at a
frame rate of 0.5 Hz to minimize microbubble destruction by the
imaging ultrasound pulses. The Doppler signal from the inflowing
contrast agent was visible in the images in color superimposed on
the grayscale image of the tumor. The power Doppler images at
peak enhancement were analyzed to determine percentage area of
the tumor with flow (PAF) and color-weighted flow area (CWFA),
representing relative blood volume flowing through the unit
volume of the tumor in the image plane [22,23].
In vitro and in vivo radiation
Cells in exponential growth phase were counted and plated in 60-
mm dishes containing 4 mL medium. The cells were allowed to
attach for 4 hours, then erlotinib was added to cultures one hour
before radiation. Cells were irradiated with a Mark I cesium
irradiator (J.L. Shepherd, San Fernando, CA) at a dose rate of
1.6 Gy/min. Colonies containing.50 cells were stained and counted
10 to 14 days after irradiation. The surviving fraction was calculated
by dividing the number of colonies formed by the total number of
cells plated, times plating efficiency. Each point on the survival curve
represents the mean surviving fraction from at least three replicates.
Irradiation of the flank bearing the tumor was performed using a
250 kV orthovoltage irradiator (Philips RT 250) at a dose rate of
2.63 Gy/min through a 0.2-mm copper filter. The source-to-tumor
target distance was 30 cm with adequate shielding of non-tumor sites.
Broadband diffuse reflectance spectroscopy
To quantify tissue optical properties and determine tissue
hemoglobin oxygen saturation (SO2), broadband diffuse reflec-
tance spectrometric measurements were performed prior to the
start of erlotinib therapy and after 4 days of therapy. The
instrument and the analysis algorithm have been described in
detail in previous publications [24,25]. Briefly, the instrument
consists of a 250-W quartz tungsten halogen lamp, a hand-held
surface contact fiber optic probe, a spectrograph, and a liquid
nitrogen–cooled CCD camera to image the reflectance spectra
from multiple detection fibers simultaneously. For this experiment,
the reflectance spectra in 600–800 nm range from source-detector
distances between 1.2 to 4.0 mm were used for data analysis. The
data was fit to the analytical solutions of photon diffusion equation
for semi-infinite geometry to calculate tissue concentrations of oxy-
hemoglobin (HbO2) and deoxy-hemoglobin (Hb). From this
information, the total hemoglobin concentration
(THC=cHbO2+cHb) and the tissue hemoglobin oxygen satura-
tion (SO2=cHbO2/THC) were derived. In previous study, the
broadband diffuse reflectance spectroscopy was validated through
reproducing the oxy-hemoglobin dissociation curve for a tissue
phantom of mouse erythrocytes, and by correlating pO2 measured
by Eppendorf pO2 histograph and SO2 of in vivo mice with varying
oxygenation. The dissociation curve matched the published values
closely (, 5% difference) and the correlation coefficient of in vivo
mice was 0.90 (23).
Detection of hypoxia with EF5
EF5 is a 2-nitroimidazole that forms covalent protein adducts in
viable hypoxic cells in a manner that is inversely proportional to
oxygen concentration in the physiologic range [26]. Details
regarding its use in assessing tumor oxygenation in human tumors
and human tumor xenografts in rodent models are provided
elsewhere [27–29]. EF5 studies were performed after five days of
erlotinib therapy.
Briefly, mice were injected with 10 mmol/L drug in 2.4%
ethanol and 5% dextrose intravenously (0.01 ml/g body weight),
followed by an equal volume intraperitoneal injection 30 minutes
later. Three hours after the first EF5 injection, mice were
euthanized. The tumor was resected and frozen in OTC
compound (Sakura Finetek Torrance, CA) by using dry ice. For
analysis of hypoxia, 10 mm sections were cut onto poly-L-lysine–
coated slides, fixed in 4% paraformaldehyde for 1 hour, and then
rinsed and blocked for 2 hours at room temperature. Slides were
stained with Cy3-conjugated ELK3-51, a mouse monoclonal
antibody to EF5. Just prior to imaging, tissue sections were dipped
briefly into a 25 mM Hoechst 33342 solution. This stains the
nuclei, which can then also be imaged, prior to the imaging of
EF5, over the same coordinates.
Determination of tumor growth delay
Xenografts were grown as described above. The mice were
started on erlotinib, given cisplatin or irradiated when the tumors
reached approximately 1 cm in diameter. Mice were examined
twice weekly for evaluation of tumor growth. Tumors were
measured with calipers in three mutually perpendicular diameters
(a, b, and c) and the volume was calculated as V=(p/ 6 )xaxbxc .
Confocal microscopy and tomato lectin studies
Mice bearing xenografts tumors were fed with erlotinib diet
(treated) or diet only (control) for 4 days. Then mice were
intravenously injected FITC conjugated tomato (Lycoperscion
esculentum) lectin (Vector Laboratories) to label perfused vessels.
After 30 minutes, tumors were excised and frozen in OCT (Sakura
Fineteck, Torrance, CA) using liquid nitrogen. Thereafter,
100 mm section(s) were used to perform confocal microscopy.
Erlotinib Alters Vascularity
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Samples were sent to ESA Laboratories. Inc. (Chelmsford, MA)
for cisplatin determination using graphite furnace atomic absorp-
tion spectrometry [30]. The tissue samples were prepared using an
acid digestion method in which the sample is heated in HNO3 and
H2O2. The sample was then brought up to final volume in dilute
HCl and analyzed by AAS Graphite Furnace (Perkin Elmer 600)
with a detection limit of 25 ng. Prior to cisplatin determination on
mice treated with the drug, standardization was performed using
tumors taken from five non-cisplatin treated mice.
Statistical analysis
Models were constructed to analyze the effects on the treatment
on tumor growth rate, which was summarized as the time to reach
a target tumor volume. If the data were complete (e.g., all animals
reached the target volume) then a linear regression model was
employed. However, if the data were censored (e.g., animals
expired or were sacrificed prior to reaching the target volume) a
Cox regression model was employed. As described previously [31],
a regression model was fit to time to tumor volume data that
included terms to target tumor volume data that included terms to
estimate the individual (main) effects of each treatment and the
interaction of these two treatments on the tumor regrowth. For the
cisplatin/erlotinib experiments, the linear model took the form:
Y ~ b0 z b1 cisplatin ðÞ z b2 erlotinib ðÞ
z b3 cisplatin x erlotinib ðÞ
Y=days to reach a target tumor volume during the observation
period, cisplatin, and erlotinib are indicators for the treatment
received (1=yes, 0=no) and cisplatin x erlotinib is an interaction
term. The test of interaction between cisplatin and erlotinib was
conducted on the interaction term using a one-sided Wald statistic
to determine whether b3.0, indicating synergy, defined as a more
than additive effect. Due to censoring (i.e., animals expired or were
sacrificed prior to reaching the target volume) of approximately
30% of animals in the erlotinib and radiation experiments, a Cox
regression model was fit to time to target tumor volume data that
included terms for the main effects of erlotinib and radiation and
the interaction between these two treatments. Wald test of synergy
was similar to that described above. With no censoring of animals
in the cisplatin/erlotinib sequence experiments, the comparison of
time to reach a target tumor volume among control, erloti-
nibRcisplatin and cisplatin R erlotinib groups was performed by
ANOVA. Post-hoc paired group comparisons were performed by
Scheffe testing to control the overall type I error rate. A
significance level of 0.05 was considered to be statistically
significant. Regression modeling and group comparisons, as
described above, were performed in SPSS 12.0 (SPSS, Inc.,
Chicago, IL).
Unpaired Student’s t-tests were used for comparisons between
groups of tumors or dishes of cells. Paired t-tests were used for
comparison within individual tumors before and after treatment.
These statistics were calculated using KaleidaGraph (version 3.6.2;
Synergy Software, Reading, PA).
Results
EGFR inhibition downregulates HIF-1a and VEGF
expression in vitro and in vivo
Our previous work demonstrated that small molecule EGFR
inhibitors including erlotinib decreased VEGF mRNA expression,
decreased secretion of VEGF protein, and blunted HIF-1a
induction in response to hypoxia in SQ20B head and neck
squamous cell carcinoma cells [20]. We extended these studies by
using siRNA directed against EGFR. This also led to a decrease in
HIF-1a induction in response to 1% oxygen by approximately
50% (Fig. 1A). Likewise, treatment of these cells with the anti-
EGFR monoclonal antibody cetuximab also attenuated HIF-1a
induction in response to hypoxia (Fig. 1B).
To determine the effects of EGFR inhibition in vivo and to
examine their consequences, we implanted SQ20B cells subcuta-
neously in nude mice. When these cells formed tumors
approximately 1 cm in diameter, host mice were fed a control
diet or a diet containing erlotinib for 4 days to deliver 50 mg/kg/
day. After five days, mice were sacrificed, and tumors were
excised. Each tumor was divided in two and processed for either
Western blotting or ELISA. Western blotting showed that erlotinib
almost completely abolished p-Akt and HIF-1a expression in vivo
(Fig 1C), similar to what was seen in vitro. Erlotinib also led to an
approximately a 50% decrease in VEGF expression (Fig. 1D).
In order to show that these results were not unique to SQ20B
cells, we repeated the experiments in two other cells lines. Figs. 1E
and 1F show that erlotinib blunted both HIF-1a expression and
secretion of VEGF protein in H226 lung carcinoma cells. Similar
results were seen in H292 lung carcinoma cells (Fig. S1).
Erlotinib alters vessel morphology and permeability in
vivo
Because HIF-1a and VEGF are intimately associated with
tumor vascularization, we examined the effect of erlotinib on
tumor vessels. Mice bearing SQ20B xenografts were injected with
tomato lectin prior to being sacrificed, and confocal microscopy
was performed on the excised tumors. This showed a change in
the vascular morphology (Fig. 2A) with the vessels in the erlotinib-
treated tumors appearing more sharply and discretely outlined
compare to vessels in control tumors. Control tumors showed
more lectin staining surrounding the vessels. This suggested that
erlotinib caused changes in vessel structure and/or permeability,
resulting in less leakage of lectin into the interstitium. To assess this
directly, we injected Evans blue dye and quantified the amount
that extravasated into the tumor interstitium. We found that
erlotinib treatment significantly decreased vascular permeability
(Fig. 2B).
Erlotinib increases tumor blood flow
The data in Fig. 2 suggested that erlotinib decreased vascular
permeability and changed vessel morphology. In order to
determine what effect this might have on tumor blood flow, we
used power Doppler ultrasound. By day 4 of erlotinib therapy,
most tumors showed an increase in tumor blood flow (Fig. 3A). We
quantified this effect using 2 different parameters, percentage area
of the tumor with flow (PAF) and color-weighted flow area
(CWFA), which are shown in Figs. 3B and 3C respectively. Using
either of these parameters we saw a statistically significant increase
in blood flow. In control mice not treated with erlotinib, there was
no increase in tumor blood flow with time (data not shown).
We repeated the Doppler studies using a different xenograft
model, H226 non-small cell lung cancer cells. In this model
erlotinib treatment also led to an improvement in blood flow
(Fig. 3D); however, in general this took longer than in SQ20B
xenografts, on the order of 6 days rather than 4 days. Analysis of
percentage area of tumor with flow confirmed a statistically
significant increase in tumor blood flow from day 0 to day 6, but
there was no difference between day 0 and day 4 (Fig. 3E).
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overnight. The next morning, cells were transfected with 150 nanomoles siRNA (either EGFR SmartPool or control non-targeted) in Optimem
transfection medium using Oligofectamine. After 24 hours, the transfection medium was replaced with fresh, prewarmed culture medium. 24 hours
after this (48 hours after transfection), cells were exposed to either 21% or 1% oxygen. Three hours later they were harvested and Western blotting
was performed. (B) SQ20B cells were treated with 10 nM cetuximab or DMSO (control) for 16 hrs, and then exposed to either 21% or 1% oxygen.
Three hours later they were harvested and Western blotting was performed. (C) Nude mice were injected subcutaneously in the flank with SQ20B
cells to form xenografts. When the tumors reached a size of 100–150 mm
3 (approximately 7–10 days after injection), half the mice (lanes 4–6) were
started on an erlotinib-containing diet (50 mg/kg/day). After 4 days of feeding, mice were sacrificed, and the tumors were removed. Half of each
tumor was lysed in protein lysis buffer, and Western blotting was performed for pAkt (S473) and HIF-1a. Each lane represents a tumor from a different
mouse. (D) The other half of each tumor from (E) was homogenized in PBS, and then ELISA for VEGF was performed. VEGF level was normalized to
tumor weights. Data shown represent mean values from 3 control mice and 3 erlotinib-treated mice. Error bars represent standard error of the mean.
p value was obtained using Student’s t-test. (E) H226 cells were treated with 10 mM erlotinib or DMSO (control) for 16 hrs, and then exposed to either
21% or 1% oxygen. Three hours later they were harvested and Western blotting was performed. (F) H226 cells were seeded then later that day they
were treated with erlotinib (10 mM) or DMSO (control). 24 hours later, the media was changed and replaced with media containing 1% serum with or
without erlotinib. Cells were exposed to 1% oxygen. 16 hours later, aliquots of supernatant were removed from dishes, and ELISA for VEGF was
performed. ELISA values were normalized to the number of cells present. Data shown represent mean values. Error bars represent standard error of
the mean. p value was obtained using Student’s t-test.
doi:10.1371/journal.pone.0006539.g001
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not shown).
Bevacizumab increases tumor blood flow
Vessel normalization and the consequent increase in tumor
vascular flow were originally seen using VEGFR2 antagonists to
directly target tumor blood vessels [8]. To see whether
improvements in tumor vascular function through targeting
EGFR achieved comparable effects as anti-VEGF therapy in our
model, we treated mice with SQ20B xenografts with the anti-
VEFR monoclonal antibody bevacizumab. Treatment of this
agent led to an increase in blood flow 4 days after injection, similar
to that seen with erlotinib (Fig. S2).
Erlotinib decreases hypoxia and increases SO2 in vivo
As vascularization could affect tumor oxygenation, we measured
hypoxia in our tumors using the 2-nitroimidazole, EF5. This agent
binds to regions of hypoxia in a manner that is inversely
proportional to oxygen concentration [26]. EF5 was injected after
5 days of erlotinib treatment, and then mice were sacrificed three
hours afterwards. Images were acquired after immunohistochem-
ical staining for EF5 (Fig. 4A). Tumors from 4 different control
mice showed patchy regions of high EF5 binding, consistent with
heterogeneous binding and the presence of markedly hypoxic
tumor regions (panels i-iv). In mice treated with erlotinib the EF5
staining was noticeably less prominent, consistent with decreased
hypoxia (Fig. 4A).
As an alternate method of assessing tumor oxygenation, we
measured tissue hemoglobin oxygen saturation (SO2) in a group of
mice prior to erlotinib therapy and on day 5 of erlotinib therapy.
Tumors were allowed to grow to approximately 1 cm in diameter
before erlotinib was started in order to have tumors of sufficient
size to perform broadband diffuse reflectance spectroscopy before
and after therapy. These tumors (n=7) also underwent power
Doppler ultrasound to assess tumor blood flow. The mean tumor
blood flow increased after 4 days of erlotinib treatment (Fig. 4B).
Optical spectroscopy showed the pre-erlotinib SO2 to be
56.463.1% (mean value6SEM). This increased to 67.162.7%
(mean value6SEM) after 4 days of erlotinib therapy (Fig. 4C;
p=0.06; Student’s t-test). Of the seven tumors in this experiment,
six showed an increase in tumor vascular perfusion after 4 days of
erlotinib therapy. All six of these tumors showed an increase in
SO2. In the single tumor that showed a decrease in vascular
perfusion, the SO2 also decreased. Therefore, there was a perfect
correlation between increasing vascular perfusion and increasing
SO2. These tissue hemoglobin oxygen saturation data support our
hypothesis that erlotinib improves tumor oxygenation in tumors
via improved vascular perfusion.
Effect of erlotinib on response to cisplatin in SQ20B head
and neck squamous cell xenografts
A predicted consequence of increased blood flow to a tumor
would be enhanced drug delivery, which would have obvious
clinical implications for the combination of anti-EGFR therapy
and chemotherapy. The agent cisplatin is the most commonly used
drug in the treatment of head and neck squamous cell cancers;
hence, we used this drug to test our hypothesis. SQ20B xenografts
were grown in nude mice. When these reached a size of
approximately 5 mm, the control set of mice were given a single
dose of cisplatin. Three hours later they were sacrificed, and the
Figure 2. Erlotinib alters vascular morphology and increases vascular permeability in vivo. (A) Nude mice were injected subcutaneously
in the flank with SQ20B cells to form xenografts. When tumors reached a size of ,1 cm in diameter, some of the mice were started on an erlotinib-
containing diet (50 mg/kg/day). After 4 days of erlotinib treatment (or control diet), FITC-conjugated tomato lectin was injected via tail vein. The mice
were euthanized, and then a 100 mm thick section of each tumor was viewed under confocal microscope. The projected photomicrograph (2006
total magnification) of sections of tumors from 2 different erlotinib-treated and 2 control mice are shown (B) Tumors were grown as described in (A).
Evans blue dye was injected intravenously. Six hours later mice were sacrificed and tumors were excised. Dye was extracted, then quantified by
reading at 620 nm in a spectrophotometer. Data shown represent mean of 3 control mice and 3 erlotinib-treated mice. Error bars represent standard
error of the mean. p value was obtained using Student’s t-test.
doi:10.1371/journal.pone.0006539.g002
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started on erlotinib-containing feed, then after four days (on day
5), the mice were sacrificed and the tumors removed. Tumors were
flash frozen in liquid nitrogen and sent to an outside laboratory to
determine the level of cisplatin in the tumors using graphite
furnace atomic absorption spectrophotometry. Fig. 5A shows that
the mice that were pre-treated with erlotinib had a higher level of
cisplatin in their tumors than did the control mice.
With a higher level of cisplatin within the tumors, we predicted
that this would lead to increased efficacy in tumor control. In
order to determine whether this was the case, we gave mice with
SQ20B xenografts a single dose of cisplatin or a 4-day course of
erlotinib followed by a dose of cisplatin on day 5. Fig. 5B shows
that the dose of cisplatin that we used was subtherapeutic, resulting
in no change in tumor regrowth compared with control mice.
Erlotinib by itself had some effect on retarding tumor regrowth,
but the single dose of cisplatin administered after 4 days of
erlotinib therapy had a much greater effect. The effect between
erlotinib and cisplatin was more than additive (test of synergy;
p,0.001 by linear regression) as shown in Fig. 5C.
If the synergistic effect of erlotinib combined with cisplatin was
primarily due to changes in the TME induced by erlotinib leading
to increased cisplatin cytotoxicity, then the order in which these two
agents are given should be critical in determining outcome. To test
this, we repeated the tumor regrowth assay, this time giving one set
of mice erlotinib for 4 days followed by a dose of cisplatin on day 5
and another set the same dose of cisplatin followed by 4 days of
erlotinib. The results, shown in Fig. 5D, unequivocally demonstrate
that the sequencing is critical. Erlotinib followed by cisplatin had a
greater effect on inhibiting tumor regrowth than the reverse
combination. There was a statistically significant difference among
the three groups in the time taken for tumors to reach a volume of
1,250 mm
3 (p=0.001) with a significantly longer time period for
erlotinibRcisplatin as compared to both control (p=0.003;
ANOVA) and cisplatinRerlotinib (p=0.006) groups.
Effects of erlotinib on radiation response
Improvement in hypoxia should theoretically lead to improved
radiation response in vivo, an idea that we tested using the tumor
regrowth delay assay. Mice bearing SQ20B tumors were assigned to
one of 4 treatment groups (radiation plus erlotinib, radiation alone,
erlotinib alone, or mock treatment). Micewere pretreated for 4 days
with erlotinib prior to irradiation (6 Gy). The results are shown in
Fig. 6A. Due to censoring of animals, survival analysis was
employed to evaluate treatment interaction. The median time to
reach a tumorvolumeof1,000 mm
3 was17days inboth the control
group and the erlotinib group. The median time increased to 24
days in the radiation and to 34 days in the radiation+erlotinib
group. The effects ontumor regrowth withthe combination therapy
appeared to be at most additive, as the test for synergy was not
Figure 3. Erlotinib increases blood flow in vivo. Mice were injected subcutaneously in the flank with SQ20B cells (panels A–C) or H226 cell
(panels D, E) to form xenografts. When tumors reached a size of ,1 cm in diameter, mice were anesthetized and injected with microbubble contrast
agent, then power Doppler ultrasound was performed. Mice were then started on an erlotinib-containing diet (50 mg/kg/day). Repeat Doppler
measurements were performed at day 4 in all mice and also at day 6 for mice with H226 xenografts. (A) Doppler flow in two mice with SQ20B
xenografts imaged pre-erlotinib and at day 4 of erlotinib treatment. Area of contrast enhancement (yellow pixels) signifies the perfused region of the
TME. (B) Percentage area of flow (PAF) was quantified in 4 SQ20B xenografts. (C) Area of color-weighted flow area (CWFA) was quantified in same 4
xenografts used in (B). (D) Doppler flow in two mice with H226 xenografts imaged pre-erlotinib and at days 4 and 6 of erlotinib treatment. (E) PAF was
quantified in 4 mice with H226 xenografts (including two shown in (D)). Figures in (B), (C) and (E) show the mean values before and after treatment
with erlotinib; bars represent the standard error of the mean. p values were calculated using paired Student’s t-test.
doi:10.1371/journal.pone.0006539.g003
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investigated the effect of erlotinib on in vitro radiosensitivity. Using a
standard clonogenic survival assay, we found that erlotinib had no
effect on the radiation survival curve in SQ20B cells (Fig. S3).
Discussion
The concept of vascular normalization, as proposed by Jain [7],
has relied primarily on the idea of targeting the tumor vasculature
via anti-VEGF or VEGFR agents. According to this model,
tumors often express high levels of VEGF, leading to aberrant
vasculature that provide inadequate blood flow to tumors. A
decrease in VEGF activity, for example by using the anti-VEGFR
agent AZD2171 can reduce interstitial fluid pressure and
‘‘normalize’’ blood vessel morphology, leading to improved
vascular perfusion [7,8]. In this report we investigate the idea of
using agents targeting the tumor cells themselves. We chose the
EGFR inhibitor erlotinib, but other agents that indirectly decrease
VEGF expression may show the same effect. Data from many
laboratories indicate that inhibition of EGFR signaling can
decrease expression of HIF-1a and VEGF [16–20], most likely
through the PI3K pathway. We confirmed that erlotinib inhibited
HIF-1a and VEGF both in vitro and in vivo in SQ20B squamous
cell carcinoma cells. The decrease in VEGF expression in vivo was
accompanied by a change in vessel morphology (Fig. 2A), a
decrease in vascular permeability (Fig. 2B) and an increase in
tumor blood flow (Fig. 3). Therefore, we hypothesize that erlotinib
treatment has an indirect effect on the vessels resulting from a
decrease in VEGF secretion by the tumor cells. Further evidence
supporting the idea that VEGF is the downstream effector
responsible for the improved blood flow comes from the fact that
in the same SQ20B tumor model, the anti-VEGF antibody
bevacizumab led to a similar improvement in blood flow (Fig. S1).
We investigated the consequences of improved tumor blood
flow in response to erlotinib. One prediction is that erlotinib pre-
treatment would alter the TME, allowing for better delivery of
chemotherapy (e.g. cisplatin) and improved therapeutic effect. Our
data confirmed both. Erlotinib pre-treatment did increase cisplatin
levels in the tumors (Fig. 5A). A single dose of cisplatin that by itself
had no effect on tumor regrowth was strongly synergistic with
erlotinib in inhibiting tumor regrowth. Furthermore, the timing of
cisplatin relative to erlotinib was critical. Erlotinib followed by
cisplatin had a much greater effect on inhibition of tumor
regrowth than did the reverse combination. This result is
consistent with the idea that erlotinib alters the TME in a way
that allows cisplatin to have a greater effect.
We also found that erlotinib treatment decreased hypoxia as it
improved blood flow. We demonstrated this by using both EF5
immunohistochemistry and by measuring tissue hemoglobin satura-
tion. Solomon et al. [32] had previously shown that the EGFR
inhibitor gefitinib decreased intratumoral hypoxia inA431 xenografts
using
18F-FAZA PET scanning with the nitroimidazole FAZA.
Another group showed that gefitinib improved tumor oxygenation in
ErbB2 expressing breast cancer xenografts using EF5 flow cytometry
[33]. Our results are entirely consistent with these studies.
Furthermore, we offer a mechanism for this phenomenon, namely
that EGFR inhibition downregulates VEGF expression, leading to
vascular normalization and improved blood flow.
A predicted consequence of decreased hypoxia would be
improved response to radiation therapy. Krause et al. provided
evidence that increased oxygenation after targeting of the EGFR
Figure 4. Erlotinib decreases hypoxia in vivo. (A) Eight mice were injected subcutaneously in the flank with SQ20B cells to form xenografts. Half
the mice were started on erlotinib feed when the tumors reached a size of ,1 cm in diameter; the other half were fed control diet. After 4 days, mice
were injected with EF5, sacrificed 3 hours later and the tumors harvested. Tumors were stained with Hoechst 33342 and with the Cy3 conjugated
anti-EF5 Elk3-51 antibody. Images represent representative sections of tumors taken from 4 erlotinib-treated mice (panels i-iv) and from 4 control
mice (panels v-viii). (B) A different set of mice was injected subcutaneously with SQ20B cells to form xenografts. When the tumors reached ,2c mi n
diameter, Doppler ultrasound and broadband diffuse reflectance spectroscopy (to determine tissue hemoglobin oxygen saturation (SO2)) were
performed. Mice were then started on erlotinib-containing diet. Four days later Doppler and optical measurements were repeated. Mean tissue
hemoglobin oxygen saturation (SO2) for these 7 tumors pre- and post-erlotinib is shown. Bars represent the standard error of the mean. p values were
calculated using paired Student’s t-test.
doi:10.1371/journal.pone.0006539.g004
Erlotinib Alters Vascularity
PLoS ONE | www.plosone.org 8 August 2009 | Volume 4 | Issue 8 | e6539by C225 might contribute to the improvement in local control
following radiation [34]. Indeed we found that there was a greater
effect on tumor regrowth when erlotinib was followed by 6 Gy of
radiation than with either treatment by itself, although this was not
a synergistic effect. We hypothesize that this lack of synergy may
be a result of the heterogeneity of tumor response. In contrast to
the effects in vivo, erlotinib had no effect in vitro in radiosensitizing
SQ20B cells (Fig. S3). We acknowledge that other groups have
found that EGFR inhibition can increase in vitro radiosensitivity.
Cetuximab has also been shown to augment radiation-induced cell
killing and to decrease the proportion of cells in S phase, a more
radioresistant phase [35]. Several groups have shown that EGFR
inhibition can decrease DNA damage repair, perhaps by altering
an interaction between EGFR and DNA-PK [17,36,37]. Chinna-
yan et al. showed that erlotinib radiosensitized cells in vitro, an effect
that might have occurred through a combination of increased
apoptosis, cell cycle arrest, and changes in DNA damage repair
[38]. Notwithstanding these results, our findings suggest that an
additional mechanism may also be operative in the improved
radiation response seen in vivo with EGFR inhibition.
Figure 5. Effect of erlotinib with cisplatin on tumor regrowth of xenografts. (A) Mice were subcutaneously implanted with SQ20B cells.
When tumors reached a size of ,5 mm in diameter, therapy was started. One group of mice (five mice) received a single dose of cisplatin (CDDP)
intraperitoneally (1 mg/kg). Three hours later, the mice were sacrificed, and tumors were removed and snap frozen in liquid nitrogen. The second
group of mice was fed an erlotinib-containing diet, and then on day 5 the mice were injected with CDDP intraperitoneally (1 mg/kg). Three hours
later, the mice were sacrificed, and tumors were removed and snap frozen in liquid nitrogen. (B) Mice were subcutaneously implanted with SQ20B
cells. When tumors reached a size of ,5 mm in diameter, therapy was started. One quarter of the mice received no therapy (control). One quarter
received a single dose of cisplatin (CDDP) intraperitoneally (1 mg/kg) on Day 1. One quarter received erlotinib feed on days 1 through 4 and the
morning of day 5 followed by a single dose of CDDP on day 5. One quarter received erlotinib feed starting on day 1 and continuing through the
morning of day 5 but no CDDP. Erlotinib was not given from day 6 onward for any group. (C) Test of synergy for regrowth delay in time to reach
tumor volume of 2,000 mm
3 (D) Mice were subcutaneously implanted with SQ20B cells. When tumors reached ,5 mm in diameter, a third of the
mice were given a single injection of CDDP (on Day 1) then later that day started on an erlotinib-containing diet that continued through day 5. A third
of the mice were given erlotinib feed on days 1 through 4 and the morning of day 5 followed by a single dose of CDDP on day 5. Erlotinib was not
given from day 6 onward for any group. A third received no therapy (control). Mean tumor volume6standard deviation of time to reach 1,250 mm
3
were 16.563.21, 17.164.22 and 26.066.40 days for control, CDDP -.erlotinib, erlotinib -.CDDP groups respectively. The three groups were
significantly different (p=0.0001; ANOVA) with the erlotinib -.CDDP group having a significantly longer time period as compared with both control
(p=0.003) and CDDP -.erlotinib (p=0.006) groups.
doi:10.1371/journal.pone.0006539.g005
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been disappointing. Approximately 10% of patients with non-
small cell lung cancer (NSCLC) (those harboring an activating
mutation of EGFR) show a dramatic shrinkage in response to the
inhibitor gefitinib [39,40], but this is unlikely to lead to long-term
cure. Most clinical trials (e.g. IDEAL, SWOG0023) have failed to
show a survival advantage with EGFR inhibitors as monotherapy
in NSCLC (reviewed in [9]).
EGFR inhibitors have also been tested in combination with
chemotherapy. Numerous preclinical studies have shown that
EGFR inhibitors can sensitize cells to chemotherapy [41–45] and
to radiotherapy [17,38,46,47]. However, several trials (e.g.
TRIBUTE, TALENT, INTACT) have failed to show a benefit
to small molecule EGFR inhibitors in combination with
chemotherapy in NSCLC (reviewed in [48]). A phase III trial in
patients with advanced pancreatic carcinoma showed that adding
erlotinib to gemcitabine resulted in a very small improvement in
overall survival (on the order of weeks) compared with gemcitabine
alone [49]. In one phase III trial, the addition of cetuximab to
cisplatin in metastatic/recurrent head and neck squamous cell
carcinoma improved tumor response rate but did not impact
survival [50]. However, a phase III trial in patients with platinum-
resistant recurrent or metastatic head and neck squamous cell
carcinoma found that the addition of cetuximab to platinum-based
chemotherapy significantly prolonged median overall survival (7.3
months to 10.1 months) [51]. One can only speculate as to why
there are such disparate results in these trials. In part, it may relate
to redundant signal transduction pathways that occur in cancers in
patients that experimental models may not reflect. Mechanisms of
resistance in specific tumors could involve activation of insulin-like
growth factor (IGF)-1 signaling, activation of Met signaling, loss of
PTEN, or mutation of K-Ras that can compensate for the
therapeutic inhibition of EGFR signaling. Additionally, certain
tumor types may be more susceptible to signaling modulation by
EGFR inhibition, perhaps because they are more reliant on the
EGFR pathway for survival. Head and neck tumors have a high
rate of EGFR overexpression [52], which may suggest that these
tumors as a class are more EGFR-dependent than other tumor
types. Also, it has been suggested that the method by which EGFR
is inhibited (antibody versus small molecule inhibitor) may be
important in what downstream events are inhibited.
The only randomized phase III trial published to date
examining radiation versus radiation plus an EGFR inhibitor
used cetuximab in locally advanced head and neck squamous cell
carcinoma [53]. This trial showed an improvement in local control
and survival favoring the combined modality group. As discussed
above, EGFR inhibition has been shown to have numerous effects
that could lead to increased in vitro radiosensitization. However,
this does not preclude an effect on the TME. It is conceivable that
the scheduling of weekly cetuximab on this trial produced
sufficient vascular normalization to improve oxygenation and
increase radiation response.
Our findings may have clinical implications. Improvement in
blood flow leading to better drug delivery or increased tumor
oxygenation offers a rationale as to why these EGFR inhibitors
might perhaps be started prior to cytotoxic therapy and continued
through this therapy. Our pre-clinical findings suggest the idea of
imaging the TME prior to and after 5–7 days of EGFR inhibitor
therapy in order to assess whether there has been any modulation of
the TME and whether in patients in whom this occurs there is any
improvement in outcome. Non-invasive imaging techniques are
currently available in the clinic that could be used to assess tumor
vascularity (i.e. DCE MRI, Power Doppler) and/or oxygenation
(e.g. PET scanning with hypoxia sensitive tracers) [54–57]; hence,
our hypothesis could be tested in a pilot clinical trial.
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